http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
-
9 Meters Biopharma (NMTR) Appoints Sarah Liu as CCO, Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
-
9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
-
9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
-
9 Meters Biopharma (NMTR) Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
-
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
-
9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
-
9 Meters Biopharma (NMTR) Reports Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide
-
9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021
-
9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
-
9 Meters Biopharma (NMTR) Appoints Samantha Ventimiglia to its Board
-
9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
-
9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
-
9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare Conference
-
9 Meters Biopharma, Inc. to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
-
9 Meters Biopharma, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
9 Meters Biopharma, Inc. to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
-
9 Meters Biopharma (NMTR) Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of MIS-C Resulting from COVID-19
-
9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021
-
9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI"
-
9 Meters Biopharma (NMTR) Announces Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity
-
9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity
-
9 Meters Biopharma, Inc. To Present at the William Blair Biotech Focus Conference
-
9 Meters Added to Russell 2000(R) and 3000(R) Indexes
-
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome
-
9 Meters Biopharma, Inc. to Present at 2021 BIO Digital
-
9 Meters Biopharma, Inc. to Present at the Jefferies Virtual Healthcare Conference
-
9 Meters Biopharma (NMTR) Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resultin
-
9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting
-
CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
-
9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
-
9 Meters Biopharma (NMTR) Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome
-
9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021
-
9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit
-
9 Meters Biopharma (NMTR) Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome
-
9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome
-
9 Meters Biopharma (NMTR) and Celiac Disease Foundation Report Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study
-
9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study
-
9 Meters Biopharma (NMTR) Announces Proposed Public Offering of Common Stock
-
9 Meters Biopharma Announces Proposed Public Offering of Common Stock
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020
-
9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update
-
9 Meters Biopharma, Inc. to Participate in the following Virtual March Investor Conferences
-
9 Meters Biopharma, Inc. Announces Chief Medical Officer's Presentation at NIH's Accelerating Progress in Celiac Disease Workshop
-
9 Meters Biopharma (NMTR) Appoints Michael Rice to Board of Directors
-
9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors
-
9 Meters Biopharma, Inc. to Present at the 23rd Annual BIO CEO & Investor Conference

